
    
      Treatment Strategy: Multicentric, parallel double blind randomized phase 2 prospective study
      comparing baricitinib (4mg/day) + narrowband UVB TL01 versus placebo + narrowband UVB TL01
      Follow-up of the study: patients included in this study will start Baricitinib 3 months
      before starting narrowband UVB TL01. Phototherapy will be performed twice a week during 6
      months. Follow-up visit will be done at week 12, 24, 36 and 48.
    
  